Joseph M. Mylotte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph M. Mylotte has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Beth Sackett
Physicians Assistant Program D'Youville College Buffalo New York
1 shared publicationMarisa Vallone
Physicians Assistant Program D'Youville College Buffalo New York
1 shared publicationMatthew Antalek
Physicians Assistant Program D'Youville College Buffalo New York
1 shared publicationSara Russell
Physicians Assistant Program D'Youville College Buffalo New York
1 shared publication
Latest Publications
- Open Access
- 25 February 2025
- Published by Patient Safety Authority in Patient Safety
- Vol. 7 (2)
Online Supplement to “High Early Mortality in Patients With Staphylococcus aureus Bloodstream Infection: A Call for Action”
This supplementary material has been provided by the authors to give readers additional information about their work.
- 25 February 2025
- Published by Patient Safety Authority in Patient Safety
- Vol. 7 (2)
Open AccessOnline Supplement to “High Early Mortality in Patients With Staphylococcus aureus Bloodstream Infection: A Call for Action”
This supplementary material has been provided by the authors to give readers additional information about their work.
- Open Access
- 25 February 2025
- Published by Patient Safety Authority in Patient Safety
- Vol. 7 (2)
High Early Mortality in Patients With Staphylococcus aureus Bloodstream Infection: A Call for Action
Objectives: More than half of all deaths within one month of identification of Staphylococcus aureus bloodstream infection (SABI) occur within seven days of the first positive culture. However, there has not been a specific evaluation of studies of early mortality in patients with SABI. The objectives were to analyze studies that reported the seven-day all-cause mortality rate in patients with SABI and risk factors for this outcome. We also hypothesized that studies of gram-negative bloodstream infection (GNBI) or all episodes of BI (gram-negative and gram-positive, including fungemia) that reported seven-day all-cause mortality might provide other methods for predicting this outcome. Methods: Early mortality was defined as death within seven days following the first day blood cultures were positive. Of 751 studies of SABI reviewed, 23 reported seven-day all-cause mortality rates. Studies were categorized into three groups: those reporting data on all SABI, methicillin-susceptible SABI, or methicillin-resistant SABI alone. Four studies of SABI evaluated risk factors for early mortality. Of 545 studies of GNBI or all episodes of BI, six evaluated factors predictive of seven-day all-cause mortality. Results: There was a significant difference in the mean seven-day all-cause mortality rate between the three groups with SABI. However, there was no significant difference between the three groups when the metric was the proportion of all deaths within the first 30 days following the first positive blood culture that occurred within the first seven days (early death proportion). Overall, the median early death proportion for 23 studies was 53% (interquartile range 49–57). Four studies reported risk factors for early mortality, but all had methodological limitations. Analysis of six studies of GNBI or all BI revealed that an acute severity of illness model (bloodstream infection mortality risk score) by itself accurately predicted seven-day all-cause mortality. Conclusions: Concordance in the early death proportion in 23 studies suggests a distinct group of patients with SABI is at risk for early mortality. However, methodologically sound studies are needed to identify all factors (clinical, diagnostic, and pathogen) associated with early mortality to evaluate methods to potentially reduce mortality in this group. Acute severity of illness models should be evaluated for predicting early mortality in patients with SABI. Plain Language Summary: Bloodstream infections in which bacteria like Staphylococcus aureus enter the bloodstream are deadly serious for patients. In fact, studies of S. aureus bloodstream infection (SABI) mortality show that among all deaths within 30 days of the first positive blood culture test, 50% of the deaths occurred within the first seven days after the positive test. However, randomized controlled treatment trials of SABI have typically excluded the patients in the “early mortality” group, resulting in an overall lower mortality rate in trials that may inflate the effectiveness of the treatment and affect how clinicians manage patients with SABI. This article analyzes studies reporting SABI early mortality and specifically focuses on studies that identified risk factors for early mortality. The findings support standardization of the definition of early mortality as “all-cause mortality within seven days of the first positive blood culture.” However, studies that evaluated risk factors for early mortality were not well designed. Future studies need to focus on improving the design for identifying risk factors for early mortality of SABI to develop interventions to potentially reduce the 30-day mortality of this infection.
- 25 February 2025
- Published by Patient Safety Authority in Patient Safety
- Vol. 7 (2)
Open AccessHigh Early Mortality in Patients With Staphylococcus aureus Bloodstream Infection: A Call for Action
Objectives: More than half of all deaths within one month of identification of Staphylococcus aureus bloodstream infection (SABI) occur within seven days of the first positive culture. However, there has not been a specific evaluation of studies of early mortality in patients with SABI. The objectives were to analyze studies that reported the seven-day all-cause mortality rate in patients with SABI and risk factors for this outcome. We also hypothesized that studies of gram-negative bloodstream infection (GNBI) or all episodes of BI (gram-negative and gram-positive, including fungemia) that reported seven-day all-cause mortality might provide other methods for predicting this outcome. Methods: Early mortality was defined as death within seven days following the first day blood cultures were positive. Of 751 studies of SABI reviewed, 23 reported seven-day all-cause mortality rates. Studies were categorized into three groups: those reporting data on all SABI, methicillin-susceptible SABI, or methicillin-resistant SABI alone. Four studies of SABI evaluated risk factors for early mortality. Of 545 studies of GNBI or all episodes of BI, six evaluated factors predictive of seven-day all-cause mortality. Results: There was a significant difference in the mean seven-day all-cause mortality rate between the three groups with SABI. However, there was no significant difference between the three groups when the metric was the proportion of all deaths within the first 30 days following the first positive blood culture that occurred within the first seven days (early death proportion). Overall, the median early death proportion for 23 studies was 53% (interquartile range 49–57). Four studies reported risk factors for early mortality, but all had methodological limitations. Analysis of six studies of GNBI or all BI revealed that an acute severity of illness model (bloodstream infection mortality risk score) by itself accurately predicted seven-day all-cause mortality. Conclusions: Concordance in the early death proportion in 23 studies suggests a distinct group of patients with SABI is at risk for early mortality. However, methodologically sound studies are needed to identify all factors (clinical, diagnostic, and pathogen) associated with early mortality to evaluate methods to potentially reduce mortality in this group. Acute severity of illness models should be evaluated for predicting early mortality in patients with SABI. Plain Language Summary: Bloodstream infections in which bacteria like Staphylococcus aureus enter the bloodstream are deadly serious for patients. In fact, studies of S. aureus bloodstream infection (SABI) mortality show that among all deaths within 30 days of the first positive blood culture test, 50% of the deaths occurred within the first seven days after the positive test. However, randomized controlled treatment trials of SABI have typically excluded the patients in the “early mortality” group, resulting in an overall lower mortality rate in trials that may inflate the effectiveness of the treatment and affect how clinicians manage patients with SABI. This article analyzes studies reporting SABI early mortality and specifically focuses on studies that identified risk factors for early mortality. The findings support standardization of the definition of early mortality as “all-cause mortality within seven days of the first positive blood culture.” However, studies that evaluated risk factors for early mortality were not well designed. Future studies need to focus on improving the design for identifying risk factors for early mortality of SABI to develop interventions to potentially reduce the 30-day mortality of this infection.
- 9 August 2023
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 24 (11) , 1619-1628
Determining the Appropriateness of Initiating Antibiotic Therapy in Nursing Home Residents
- 9 August 2023
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 24 (11) , 1619-1628
Determining the Appropriateness of Initiating Antibiotic Therapy in Nursing Home Residents
- Open Access
- 14 October 2022
- Published by Qeios Ltd in Qeios Preprints
Determining Appropriateness of Antibiotic Therapy in Nursing Home Residents: A Review
Upwards of 70% of nursing home residents receive at least one course of antibiotics yearly but as many as 75% of these courses have been considered inappropriate. In response to this potential overprescribing of antibiotic nursing homes are now required to have an antimicrobial stewardship program to monitor and improve prescribing. However, determining appropriateness of antibiotic therapy in the nursing home setting has been a major challenge. The objectives of this review were to identify and review studies of appropriateness of antibiotic therapy in nursing homes with special focus on the criteria utilized for determining appropriateness. Of the 30 studies identified in the literature review, 50% utilized infection surveillance definitions that were not designed to assess appropriateness of antibiotic therapy in individual residents. There was also variation in the size of study populations, study design, and criteria for identifying the study population. These limitations not only make comparisons among studies problematic but also raise concerns about the validity of the findings regarding the level of appropriateness of antibiotic prescribing in nursing homes. Suggestions are provided for the design of future studies of antibiotic appropriateness in nursing homes that focus on standardizing the methodology to minimize the variation observed in the studies in this review.
- 14 October 2022
- Published by Qeios Ltd in Qeios Preprints
Open AccessDetermining Appropriateness of Antibiotic Therapy in Nursing Home Residents: A Review
Upwards of 70% of nursing home residents receive at least one course of antibiotics yearly but as many as 75% of these courses have been considered inappropriate. In response to this potential overprescribing of antibiotic nursing homes are now required to have an antimicrobial stewardship program to monitor and improve prescribing. However, determining appropriateness of antibiotic therapy in the nursing home setting has been a major challenge. The objectives of this review were to identify and review studies of appropriateness of antibiotic therapy in nursing homes with special focus on the criteria utilized for determining appropriateness. Of the 30 studies identified in the literature review, 50% utilized infection surveillance definitions that were not designed to assess appropriateness of antibiotic therapy in individual residents. There was also variation in the size of study populations, study design, and criteria for identifying the study population. These limitations not only make comparisons among studies problematic but also raise concerns about the validity of the findings regarding the level of appropriateness of antibiotic prescribing in nursing homes. Suggestions are provided for the design of future studies of antibiotic appropriateness in nursing homes that focus on standardizing the methodology to minimize the variation observed in the studies in this review.
- 2 March 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (1) , 82-87
Nursing home-associated bloodstream infection: A scoping review
Objective: To update a 2005 review of nursing home–associated bloodstream infection (NHABSI) regarding sources, organisms, antibiotic resistance, and outcome.Methods: A scoping review of studies of NHABSI identified by searching Google Scholar and Medline with OVID for the period January 1, 2004, to June 30, 2021, was conducted.Results: Overall, 6 studies of NHABSI were identified. Only 1 study was conducted with residents in North American facilities whereas in the 2005 review all studies were conducted in North America. Escherichia coli was the most common blood isolate, the urinary tract was the most common source of NHABSI; and the case-fatality rates ranged from 21% to 28%. These findings were comparable to those in the 2005 review. However, the proportion of NHABSI episodes due to antibiotic-resistant organisms increased substantially compared to the 2005 review. The most common antibiotic-resistant organisms were extended-spectrum β-lactamase–producing E. coli and Klebsiella spp. The 2 studies that evaluated the relationship between appropriate empiric antibiotic therapy and outcome came to different conclusions.Conclusions: The only major difference between the 2 reviews in the epidemiology of NHABSI was the marked increase in antibiotic resistance among blood isolates. Despite the increased antibiotic resistance, the case fatality rates in the current review were comparable to those reported in the 2005 review. However, the impact of appropriate empiric antibiotic therapy on outcome of NHABSI remains unclear.
- 2 March 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (1) , 82-87
Nursing home-associated bloodstream infection: A scoping review
Objective: To update a 2005 review of nursing home–associated bloodstream infection (NHABSI) regarding sources, organisms, antibiotic resistance, and outcome.Methods: A scoping review of studies of NHABSI identified by searching Google Scholar and Medline with OVID for the period January 1, 2004, to June 30, 2021, was conducted.Results: Overall, 6 studies of NHABSI were identified. Only 1 study was conducted with residents in North American facilities whereas in the 2005 review all studies were conducted in North America. Escherichia coli was the most common blood isolate, the urinary tract was the most common source of NHABSI; and the case-fatality rates ranged from 21% to 28%. These findings were comparable to those in the 2005 review. However, the proportion of NHABSI episodes due to antibiotic-resistant organisms increased substantially compared to the 2005 review. The most common antibiotic-resistant organisms were extended-spectrum β-lactamase–producing E. coli and Klebsiella spp. The 2 studies that evaluated the relationship between appropriate empiric antibiotic therapy and outcome came to different conclusions.Conclusions: The only major difference between the 2 reviews in the epidemiology of NHABSI was the marked increase in antibiotic resistance among blood isolates. Despite the increased antibiotic resistance, the case fatality rates in the current review were comparable to those reported in the 2005 review. However, the impact of appropriate empiric antibiotic therapy on outcome of NHABSI remains unclear.
- 2 October 2021
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 13 (4) , 153-164
Models for Assessing Severity of Illness in Patients with Bloodstream Infection: a Narrative Review
- 2 October 2021
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 13 (4) , 153-164
Models for Assessing Severity of Illness in Patients with Bloodstream Infection: a Narrative Review
- 1 March 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (3) , 366-374
Risk adjustment for benchmarking nursing home infection surveillance data: A narrative review
- 1 March 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (3) , 366-374
Risk adjustment for benchmarking nursing home infection surveillance data: A narrative review
- 11 November 2020
- Published by Springer Nature in Drugs & Aging
- Vol. 38 (1) , 29-41
Decision Tools and Studies to Improve the Diagnosis of Urinary Tract Infection in Nursing Home Residents: A Narrative Review
The overdiagnosis of urinary tract infection (UTI) in nursing home residents that results in unnecessary antibiotic treatment has been recognized for more than 2 decades. This has resulted in the publication of several decision tools for the diagnosis of UTI in nursing home residents. Given all of the decision tools available, how does one decide on the approach to improve the diagnosis of UTI in nursing home residents in the context of an antimicrobial stewardship program? To address this question, this paper reviews: (a) published decision tools for the diagnosis of UTI in nursing home residents; (b) randomized controlled trials to improve the diagnosis of UTI in nursing home residents; and (c) non-randomized studies to improve the diagnosis of UTI in nursing home residents. Review of published decision tools indicates that the diagnosis of UTI is based on the presence of urinary tract signs and symptoms. However, there is considerable variation in the diagnostic criteria among the decision tools and there is no consensus as to the best clinical criteria for the diagnosis of UTI in nursing home residents. Review of four randomized controlled trials of interventions to improve the diagnosis of UTI in nursing home residents found that different interventions and outcome measures of varying complexity were utilized. Although randomized controlled trials were, to some extent, successful, it was not clear in any trial if one or more components of an intervention contributed the most to the success and there was no evidence that an intervention was feasible or sustainable after a trial was completed. Review of non-randomized trials to improve the diagnosis of UTI in nursing home residents all had methodologic limitations that make interpretation problematic. Randomized controlled trials and non-randomized studies all focused on the process before an antibiotic is prescribed. An alternative approach that focuses on assessment of the post-prescription process (antibiotic time-out protocol) is reviewed; initial studies of this protocol were inconclusive because of design limitations and additional studies are required. Regardless of what interventions are utilized, there must be provider and nursing staff commitment and motivation to improve the management of residents with suspected UTI and methods to achieve improvement must be demonstrated to be feasible and sustainable given the resources available in nursing homes.
- 11 November 2020
- Published by Springer Nature in Drugs & Aging
- Vol. 38 (1) , 29-41
Decision Tools and Studies to Improve the Diagnosis of Urinary Tract Infection in Nursing Home Residents: A Narrative Review
The overdiagnosis of urinary tract infection (UTI) in nursing home residents that results in unnecessary antibiotic treatment has been recognized for more than 2 decades. This has resulted in the publication of several decision tools for the diagnosis of UTI in nursing home residents. Given all of the decision tools available, how does one decide on the approach to improve the diagnosis of UTI in nursing home residents in the context of an antimicrobial stewardship program? To address this question, this paper reviews: (a) published decision tools for the diagnosis of UTI in nursing home residents; (b) randomized controlled trials to improve the diagnosis of UTI in nursing home residents; and (c) non-randomized studies to improve the diagnosis of UTI in nursing home residents. Review of published decision tools indicates that the diagnosis of UTI is based on the presence of urinary tract signs and symptoms. However, there is considerable variation in the diagnostic criteria among the decision tools and there is no consensus as to the best clinical criteria for the diagnosis of UTI in nursing home residents. Review of four randomized controlled trials of interventions to improve the diagnosis of UTI in nursing home residents found that different interventions and outcome measures of varying complexity were utilized. Although randomized controlled trials were, to some extent, successful, it was not clear in any trial if one or more components of an intervention contributed the most to the success and there was no evidence that an intervention was feasible or sustainable after a trial was completed. Review of non-randomized trials to improve the diagnosis of UTI in nursing home residents all had methodologic limitations that make interpretation problematic. Randomized controlled trials and non-randomized studies all focused on the process before an antibiotic is prescribed. An alternative approach that focuses on assessment of the post-prescription process (antibiotic time-out protocol) is reviewed; initial studies of this protocol were inconclusive because of design limitations and additional studies are required. Regardless of what interventions are utilized, there must be provider and nursing staff commitment and motivation to improve the management of residents with suspected UTI and methods to achieve improvement must be demonstrated to be feasible and sustainable given the resources available in nursing homes.
- 1 March 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (3) , 315-321
Nursing Home-Associated Pneumonia, Part II: Etiology and Treatment
- 1 March 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (3) , 315-321
Nursing Home-Associated Pneumonia, Part II: Etiology and Treatment
- 1 March 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (3) , 308-314
Nursing Home–Associated Pneumonia, Part I: Diagnosis
- 1 March 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (3) , 308-314
Nursing Home–Associated Pneumonia, Part I: Diagnosis